ErratumCorrectionClinical Journal of the American Society of Nephrology 11(9):p 1721, September 2016. | DOI: 10.2215/CJN.07690716 Free Metrics Sarcina C, Tinelli C, Ferrario F, Pani A, De Silvestri A, Scaini P, Del Vecchio L, Alberghini E, Buzzi L, Baragetti I, Pozzi C. Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy. Clin J Am Soc Nephrol 11: , 2016. Due to author error, Table 2 contains several incorrect values. The corrected values are bolded below: Table 2. - Multivariate analysis evaluating association between treatment and time-average proteinuria over time Parameter Coefficient (95% CI) P Value Model 1  Proteinuria at baseline, g/d    <2 Reference    2–2.9 0.73 (0.38–1.08) <0.001    ≥3 2.02 (1.17–2.88) <0.001  Treatment    None Reference    CS −0.96 (−1.17 to −0.75) <0.001    CS+A −0.88 (−1.10 to −0.66) <0.001  Use of RAS blockers 0.16 (0.02–0.30) 0.12  eGFR at baseline    ≥60 ml/min per 1.73 m 2 (CKD 1–2) Reference    30–59.9 ml/min per 1.73 m 2 (CKD 3) 0.14 (0.02–0.26) <0.001    <30 ml/min per 1.73 m 2 (CKD 4) 0.47 (0.26–0.68) <0.001  Interaction between TAp at baseline and treatment    TAp<2 g/d and no treatment Reference    TAp 2–2.9 g/d and CS −0.37 (−0.76 to 0.01) 0.06    TAp 2–2.9 g/d and CS+A −0.43 (−0.84 to −0.02) 0.04    TAp≥3 g/d and no treatment NP    TAp≥3 g/d and CS −1.44 (−2.32 to −0.57) 0.001    TAp≥3 g/d and CS+A −0.66 (−1.54 to 0.22) 0.14 Model 2  eGFR at baseline    CKD 1–2 Reference    CKD 3 −0.27 (−0.73 to 0.20) 0.26    CKD 4 1.29 (0.96–1.62) <0.001  Treatment    None Reference    CS −1.21 (−3.14 to −1.02) <0.001    CS+A −0.99 (−1.19 to −0.78) <0.001  Use of RAS blockers 0.11 (−0.03 to 0.25) 0.12  Proteinuria (g/d) at baseline    <2 g/d Reference    2–2.9 g/d 0.39 (0.27–0.51) <0.001    ≥3 g/d 0.92 (0.77–1.07) <0.001  Interaction between eGFR at baseline and treatment    CKD 1–2 and no treatment Reference    CKD 3 and CS 0.57 (0.08–1.06) 0.02    CKD 3 and CS+A 0.32 (−0.18 to 0.83) 0.21    CKD 4 and no treatment NP    CKD 4 and CS −1.17 (−1.58 to −0.77) <0.001    CKD 4 and CS+A NP Model 1: model with interaction between proteinuria at baseline and treatment; model 2: model with interaction between eGRF at baseline and treatment. Results are expressed as coefficient with their 95% confidence interval (95% CI); the coefficient represents the mean variation of outcomes for unit difference of quantitative predictors or between levels of categorical or ordinal predictors. CS, corticosteroids; CS+A: corticosteroids plus azathioprine; RAS, renin-angiotensin system; TAp, time-average proteinuria. NP, not possible for collinearity and empty strata. Published online ahead of print. Publication date available at www.cjasn.org.Keywords:Erratum; correction; proteinuria; Corticosteroids; Azathioprine; nephropathy Copyright © 2016 by the American Society of NephrologyView full article text